Literature DB >> 28340179

Open-Label Pilot Study to Compare the Safety and Immunogenicity of Pentavalent Rotavirus Vaccine (RV5) Administered on an Early Alternative Dosing Schedule with Those of RV5 Administered on the Recommended Standard Schedule.

Ezzeldin Saleh1, Brian Eichner2, Douglas W Clark2, Martha E Gagliano2, James M Troutman2, Lynn Harrington3, Monica McNeal4, Dennis Clements5.   

Abstract

This study compares the safety and immunogenicity of pentavalent rotavirus vaccine (RV5) administered on an alternative schedule (initiated at 2-5 weeks of age) with those of RV5 administered on the recommended standard schedule. Our findings support the future conduct of larger clinical trials to confirm the safety and efficacy of rotavirus vaccination in the neonatal period.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 28340179      PMCID： PMC5907846          DOI： 10.1093/jpids/pix005

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


  10 in total

1.  Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.

Authors:  Julie E Bines; Margaret Danchin; Pamela Jackson; Amanda Handley; Emma Watts; Katherine J Lee; Amanda West; Daniel Cowley; Mee-Yew Chen; Graeme L Barnes; Frances Justice; Jim P Buttery; John B Carlin; Ruth F Bishop; Barry Taylor; Carl D Kirkwood
Journal:  Lancet Infect Dis       Date:  2015-08-26       Impact factor: 25.071

2.  Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Authors:  Timo Vesikari; David O Matson; Penelope Dennehy; Pierre Van Damme; Mathuram Santosham; Zoe Rodriguez; Michael J Dallas; Joseph F Heyse; Michelle G Goveia; Steven B Black; Henry R Shinefield; Celia D C Christie; Samuli Ylitalo; Robbin F Itzler; Michele L Coia; Matthew T Onorato; Ben A Adeyi; Gary S Marshall; Leif Gothefors; Dirk Campens; Aino Karvonen; James P Watt; Katherine L O'Brien; Mark J DiNubile; H Fred Clark; John W Boslego; Paul A Offit; Penny M Heaton
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

3.  Potential impact of accelerating the primary dose of rotavirus vaccine in infants.

Authors:  Elizabeth E Halvorson; Timothy R Peters; Beverly M Snively; Katherine A Poehling
Journal:  Vaccine       Date:  2012-02-26       Impact factor: 3.641

4.  All-cause gastroenteritis and rotavirus-coded hospitalizations among US children, 2000-2009.

Authors:  Rishi Desai; Aaron T Curns; Claudia A Steiner; Jacqueline E Tate; Manish M Patel; Umesh D Parashar
Journal:  Clin Infect Dis       Date:  2012-04-27       Impact factor: 9.079

5.  Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period.

Authors:  George E Armah; Albert Z Kapikian; Timo Vesikari; Nigel Cunliffe; Robert M Jacobson; D Bruce Burlington; Leonard P Ruiz
Journal:  J Infect Dis       Date:  2013-04-18       Impact factor: 5.226

6.  Neonatal administration of rhesus rotavirus tetravalent vaccine.

Authors:  Timo Vesikari; Aino Karvonen; Bruce D Forrest; Yasutaka Hoshino; Robert M Chanock; Albert Z Kapikian
Journal:  Pediatr Infect Dis J       Date:  2006-02       Impact factor: 2.129

7.  Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Margaret M Cortese; Umesh D Parashar
Journal:  MMWR Recomm Rep       Date:  2009-02-06

8.  Effectiveness of pentavalent rotavirus vaccine against severe disease.

Authors:  Mary Allen Staat; Daniel C Payne; Stephanie Donauer; Geoffrey A Weinberg; Kathryn M Edwards; Peter G Szilagyi; Marie R Griffin; Caroline B Hall; Aaron T Curns; Jon R Gentsch; Shelia Salisbury; Gerry Fairbrother; Umesh D Parashar
Journal:  Pediatrics       Date:  2011-07-18       Impact factor: 7.124

9.  Protective effect of natural rotavirus infection in an Indian birth cohort.

Authors:  Beryl P Gladstone; Sasirekha Ramani; Indrani Mukhopadhya; Jayaprakash Muliyil; Rajiv Sarkar; Andrea M Rehman; Shabbar Jaffar; Miren Iturriza Gomara; James J Gray; David W G Brown; Ulrich Desselberger; Sue E Crawford; Jacob John; Sudhir Babji; Mary K Estes; Gagandeep Kang
Journal:  N Engl J Med       Date:  2011-07-28       Impact factor: 91.245

10.  Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013.

Authors:  Jacqueline E Tate; Anthony H Burton; Cynthia Boschi-Pinto; Umesh D Parashar
Journal:  Clin Infect Dis       Date:  2016-05-01       Impact factor: 9.079
  10 in total
  4 in total

1.  Vaccines for preventing rotavirus diarrhoea: vaccines in use.

Authors:  Karla Soares-Weiser; Hanna Bergman; Nicholas Henschke; Femi Pitan; Nigel Cunliffe
Journal:  Cochrane Database Syst Rev       Date:  2019-10-28

2.  Vaccines for preventing rotavirus diarrhoea: vaccines in use.

Authors:  Karla Soares-Weiser; Hanna Bergman; Nicholas Henschke; Femi Pitan; Nigel Cunliffe
Journal:  Cochrane Database Syst Rev       Date:  2019-03-25

Review 3.  Vaccine responses in newborns.

Authors:  Anja Saso; Beate Kampmann
Journal:  Semin Immunopathol       Date:  2017-11-09       Impact factor: 9.623

Review 4.  Neonatal vaccine effectiveness and the role of adjuvants.

Authors:  Isaac G Sakala; Katherine Marie Eichinger; Nikolai Petrovsky
Journal:  Expert Rev Clin Immunol       Date:  2019-07-25       Impact factor: 4.473
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.